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The ongoing pandemic spread of a novel human coronavirus, SARS-COV-2, associated 20 
with severe pneumonia disease (COVID-19), has resulted in the generation of tens of 21 
thousands of virus genome sequences. The rate of genome generation is unprecedented, yet 22 
there is currently no coherent nor accepted scheme for naming the expanding phylogenetic 23 
diversity of SARS-CoV-2. We present a rational and dynamic virus nomenclature that uses 24 
a phylogenetic framework to identify those lineages that contribute most to active spread. 25 
Our system is made tractable by constraining the number and depth of hierarchical lineage 26 
labels and by flagging and de-labelling virus lineages that become unobserved and hence 27 
are likely inactive. By focusing on active virus lineages and those spreading to new 28 
locations this nomenclature will assist in tracking and understanding the patterns and 29 
determinants of the global spread of SARS-CoV-2. 30 
 31 
  32 
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There are currently more than 35,000 publicly available complete or near-complete genome 33 
sequences of SARS-CoV-2 (as of 1st June 2020) and the number continues to grow. This 34 
remarkable achievement has been made possible by the rapid genome sequencing and online 35 
sharing of SARS-CoV-2 genomes by public health and research teams worldwide. These 36 
genomes have the potential to provide invaluable insights into the ongoing evolution and 37 
epidemiology of the virus during the pandemic, and will likely play an important role in 38 
surveillance and its eventual mitigation and control. Despite such a wealth of data, there is 39 
currently no coherent system for naming and discussing the growing number of phylogenetic 40 
lineages that comprise the population diversity of this virus, with conflicting ad hoc and informal 41 
systems of virus nomenclature in circulation. A nomenclature system for the genetic diversity of 42 
SARS-CoV-2 (a clade within the species Severe acute respiratory syndrome-related virus, sub-43 
genus Sarbecovirus, genus Betacoronavirus, family Coronaviridae1) is urgently required before 44 
scientific literature and communication become further confused. 45 
 46 
There is no universal approach to classifying virus genetic diversity below the level of a virus 47 
species2, and this is not covered by the International Committee on Taxonomy of Viruses 48 
(ICTV). Typically, genetic diversity is categorised into distinct ‘clades’, each of which 49 
corresponds to a monophyletic group on a phylogenetic tree. These clades may be referred to by 50 
a variety of terms, such as ‘subtypes’, ‘genotypes’, ‘groups’, depending on the taxonomic level 51 
under investigation or the established scientific literature for the virus in question. The clades 52 
usually reflect an attempt to divide pathogen phylogeny and genetic diversity into a set of 53 
groupings that are approximately equally divergent, mutually exclusive and statistically well 54 
supported. All genome sequences are therefore allocated to one clade or provisionally labelled as 55 
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‘unclassified’. Often multiple hierarchical levels of classification exist for the same pathogens, 56 
such as the terms ‘type’, ‘group’ and ‘subtype’ that are used in the field of HIV research. 57 
 58 
Such classification systems are useful for discussing epidemiology and transmission when the 59 
number of taxonomic labels remains roughly constant through time; this is the case for slowly-60 
evolving pathogens (for example, many bacteria) and for rapidly-evolving viruses with low rates 61 
of lineage turnover (for example, HIV3 and HCV4). In contrast, some rapidly-evolving viruses 62 
such as influenza A are characterised by high rates of lineage turnover, so that the genetic 63 
diversity circulating in any particular year largely emerges out of and replaces the diversity 64 
present in the preceding few years. For human seasonal influenza, this behaviour is the result of 65 
strong natural selection among competing lineages. In such circumstances a more explicitly 66 
phylogenetic classification system is used; for example, avian influenza viruses are classified 67 
into ‘subtypes’, ‘clades’ and ‘higher order clades’ according to several quantitative criteria5. 68 
Such a system can provide a convenient way to refer to the emergence of new (and potentially 69 
antigenically-distinct) variants and is suitable for the process of selecting the component viruses 70 
for the regularly-updated influenza vaccine. A similar approach to tracking antigenic diversity 71 
may be needed to inform SARS-CoV-2 vaccine design efforts. While useful, we recognise that 72 
dynamic nomenclature systems based on genetic distance thresholds have the potential to over-73 
accumulate cumbersome lineage names. 74 
 75 
In an ongoing and rapidly changing epidemic, such as SARS-CoV-2, a nomenclature system can 76 
facilitate real-time epidemiology by providing commonly-agreed labels to refer to viruses 77 
circulating in different parts of the world, thereby revealing the links between outbreaks that 78 
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share similar virus genomes. Further, a nomenclature system is needed to describe virus lineages 79 
that vary in phenotypic or antigenic properties (although it must be stressed that at present there 80 
is no conclusive evidence of such variation among currently available SARS-CoV-2 strains).  81 
 82 
Principles of a dynamic nomenclature system 83 
There are a number of key challenges in the development of a dynamic and utilitarian 84 
nomenclature system for SARS-CoV-2. To be valid and broadly accepted a nomenclature needs 85 
to: (i) capture local and global patterns of virus genetic diversity in a timely and coherent 86 
manner, (ii) track emerging lineages as they move among countries and between populations 87 
within each country, (iii) be sufficiently robust and flexible to accommodate new virus diversity 88 
as it is generated, and (iv) be dynamic, such that it is able to incorporate both the birth and death 89 
of viral lineages through time. 90 
 91 
A special challenge in the case of COVID-19 is that genome sequence data is being generated 92 
rapidly and at high volumes, such that by the end of the pandemic we can expect hundreds of 93 
thousands of SARS-CoV-2 genomes to have been sequenced. Any lineage naming system must 94 
therefore be capable of handling tens to hundreds of thousands of virus genomes sampled 95 
longitudinally and densely through time. Further, to be practical, any lineage naming system 96 
should have no more than one or two hundred active lineage labels, as any more would obfuscate 97 
rather than clarify discussion and will be difficult to conceptualise.  98 
 99 
To fulfil these requirements we propose a workable and practical lineage nomenclature for 100 
SARS-CoV-2 that arises from a set of fundamental evolutionary and phylogenetic principles. 101 
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Some of these principles are, necessarily, specific to the COVID-19 pandemic, reflecting the new 102 
reality of large-scale real-time generation of virus genome sequences. The nomenclature system 103 
is not intended to represent every evolutionary change in SARS-CoV-2, as these will number 104 
many thousand by the end of the pandemic. Instead, the focus is on genetic changes associated 105 
with important epidemiological and biological events. Fortunately, because of the early sampling 106 
and genome sequencing of COVID-19 cases in China, especially in Hubei province, it appears 107 
that the ‘root sequence’ of SARS-CoV-2 is known. Many of the genomes from the earliest 108 
sampled cases are genetically identical and hence also likely identical to the most recent common 109 
ancestor of all sampled viruses. This occurrence is different to previous viruses and epidemics 110 
and provides some advantages for the development of a rational and scalable classification 111 
scheme. Specifically, setting the ‘reference sequence’ to be the ‘root sequence’ forms a natural 112 
starting point, as direct comparisons in the number and position of mutations can be made with 113 
respect to the root sequence.  114 
 115 
During the early phase of the pandemic, it will be possible to unambiguously assign a genome to 116 
a lineage through the presence/absence of particular sets of mutations. However, a central 117 
component of a useful nomenclature system is that it focuses on those virus lineages that 118 
contribute most to global transmission and genetic diversity. Hence, rather than naming every 119 
new possible lineage, classification should focus on those that have exhibited onward spread in 120 
the population, particularly those that have seeded an epidemic in a new location. For example, 121 
the large epidemic in Lombardy, northern Italy, thought to have begun in early February6, has 122 
since been disseminated to other locations in northern Europe and elsewhere.  123 
 124 
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Further, because SARS-CoV-2 genomes are being generated continuously and at a similar pace 125 
to changes in virus transmission and epidemic control efforts, we expect to see a continual 126 
process of lineage generation and extinction through time. Rather than maintaining a cumulative 127 
list of all lineages that have existed since the start of the pandemic, it is more prudent to mark 128 
lineages as ‘active’, ‘unobserved’, or ‘inactive’, a designation reflecting our current 129 
understanding of whether they are actively transmitting in the population or not. Accordingly, 130 
lineages of SARS-CoV-2 documented within the last month are defined here as ‘active’, those 131 
last seen >1 month but <3 months ago are classified as ‘unobserved’, and those that have not 132 
been seen for >3 months are termed ‘inactive’. 133 
 134 
Although this strategy will allow us to track those lineages that are contributing most to the 135 
epidemic, and so reduce the number of names in use, it is important to keep open the possibility 136 
that new lineages will appear through the generation of virus genomes from unrepresented 137 
locations or from cases with travel history from such locations. For example, the epidemic in 138 
Iran, designated B.4 in our system, was identified via returning travellers to other countries7. 139 
Further, lineages that have not been seen for some time may re-emerge after a period of cryptic 140 
transmission in a region. Hence, it is possible for lineages that were previously classified as 141 
inactive or unobserved to be later re-labelled as active. We choose the term lineages (rather than 142 
‘clades’, ‘genotypes’ or other designations) for SARS-CoV-2 as it captures the fact that they are 143 
dynamic, rather than relying on a static and exclusive hierarchical structure. 144 
 145 
Lineage naming rules 146 
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We propose that major lineage labels begin with a letter. At the root of the phylogeny of SARS-147 
CoV-2 are two lineages that we simply denote as lineages A and B. The earliest lineage A 148 
viruses, such as Wuhan/WH04/2020 (EPI_ISL_406801), sampled on 2020-01-05, share two 149 
nucleotides (positions 8782 in ORF1ab and 28144 in ORF8) with the closest known bat viruses 150 
(RaTG13 and RmYN02). Different nucleotides are present at those sites in viruses assigned to 151 
lineage B, of which Wuhan-Hu-1 (GenBank accession MN908947) sampled on 2019-12-26 is an 152 
early representative. Hence, although viruses from lineage B happen to have been sequenced and 153 
published first8-10, it is likely (based on current data) that the most recent common ancestor 154 
(MRCA) of the SARS-CoV-2 phylogeny shares the same genome sequence as the early lineage 155 
A sequences (e.g. Wuhan/WH04/2020). Importantly, this does not imply that the MRCA itself 156 
has been sampled and sequenced, but rather that no mutations had accrued between the MRCA 157 
and the early lineage A genome sequences. At the time of writing, viruses from both lineages A 158 
and B are still circulating in many countries around the world, reflecting the exportation of 159 
viruses from Hubei to other regions of China and elsewhere before the strict travel restrictions 160 
and quarantine measures were imposed there. 161 
 162 
To add further lineage designations we downloaded 27,767 complete SARS-CoV-2 genomes 163 
from the GISAID database11 on 18th May, 2020 and estimated a maximum likelihood tree for 164 
these data (see Methods) (Fig. 1). We defined further SARS-CoV-2 lineages, each of which 165 
descends from either lineage A or B and is assigned a numerical value (e.g. lineage A.1, or 166 
lineage B.2). Lineage designations were made using the following set of conditions: 167 
 168 
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I. Each descendent lineage should show phylogenetic evidence of emergence from an 169 
ancestral lineage into another geographically distinct population, implying substantial 170 
onward transmission in that population. In the case of a rapidly expanding global lineage 171 
the recipient ‘population’ may comprise multiple countries. In the case of large and 172 
populous countries it may represent a new region or province. To show phylogenetic 173 
evidence a new lineage must meet all of the following criteria: (a) it exhibits one or more 174 
shared nucleotide differences from the ancestral lineage, (b) it comprises at least five 175 
genomes with >95% of the genome sequenced, (c) genomes within the lineage exhibit at 176 
least one shared nucleotide change among them, and (d) a bootstrap value >70% for the 177 
lineage defining node. Importantly, criterion (c) helps to focus attention only on lineages 178 
with evidence of on-going transmission. 179 
II. The lineages identified in step (I) can themselves act as ancestors for virus lineages that 180 
then emerge in other geographic areas or at later times, provided they satisfy criteria a-d 181 
above. This results in a new lineage designation (e.g. A.1.1). 182 
III. The iterative procedure in step II can proceed for a maximum of three sublevels (e.g. 183 
A.1.1.1) after which new descendent lineages are given a letter (in English alphabetical 184 
sequence from C, so A.1.1.1.1 would become C.1 and A.1.1.1.2 would become C.2. The 185 
rationale for this is that the system is intended only for tracking currently circulating 186 
lineages, such that we do not try to capture the entire history of a lineage in its label (that 187 
complete history can be obtained by reference to a phylogeny). At the time of writing no 188 
C level lineages have been assigned. 189 
IV. All sequences are assigned to one lineage. For example, if a genome does not meet the 190 
criteria for inclusion in a ‘higher level’ lineage (e.g. A.1.2, B.1.3.5) then it is 191 
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automatically classified into the lowest level for which it does meet the inclusion criteria, 192 
which ultimately is ‘A’ or ‘B’.   193 
 194 
Using this scheme we identified 81 viral lineages. These lineages mostly belong to A, B and B.1. 195 
We identified six lineages derived from lineage A (denoted A.1-A.6) and two descendant sub-196 
lineages of A.1 (A.1.1 and A.3). We also describe 16 lineages directly derived from lineage B. 197 
To date, lineage B.1 is the predominant known global lineage and has been subdivided into > 70 198 
sub-lineages. Lineage B.2 currently has six descendant sub-lineages. We are not yet able to 199 
further subdivide the other lineages even though some contain very large numbers of genomes. 200 
This is because many parts of the world experienced numerous imported cases followed by 201 
exponential growth in local transmission. We provide descriptions of these initial lineages, 202 
including their geographical locations and time span of sampling, in Table 1. We have also tried 203 
to be flexible with the criteria where, for example, the bootstrap value is below 70% but there is 204 
strong prior evidence that the lineage exists and is epidemiologically important. In particular, the 205 
Italian epidemic comprises two large lineages in our scheme – B.1 and B.2 – reflecting genomes 206 
from Italy as well as from large numbers of travellers from these regions and that fall into both 207 
lineages. 208 
 209 
A unique and important aspect of our proposed nomenclature is that the status of the currently 210 
circulating lineages be assessed at regular intervals, with decisions made about identifying new 211 
lineages and flagging those we believe are likely be ‘unobserved’ or ‘inactive’ because none of 212 
their members have been sequenced for a considerable time. The names of unobserved or 213 
inactive lineages will not be reassigned. These are provisional timescales and the category 214 
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thresholds may be altered in the future once the dynamics of lineage generation and extinction 215 
are better understood. When visualising the epidemic we suggest that these lineages should be no 216 
longer labelled to reduce both the number of names in circulation and visual noise, and to focus 217 
on the current epidemiological situation.  218 
 219 
Discussion 220 
While we regard this proposed nomenclature as practical and robust, it is important to recognise 221 
that phylogenetic inference carries statistical uncertainty and much of the available genome data 222 
is noisy, with incomplete genome coverage and errors arising from the amplification and 223 
sequencing processes. We have proposed a genome coverage threshold for proposing new 224 
lineages (see above), and we further suggest that sequences are not ascribed a lineage 225 
designation unless the genome coverage of that sequence exceeds 70% of the coding region. As 226 
noted above, when SARS-CoV-2 genetic diversity is low during the early pandemic period, there 227 
will be a direct association between lineage assignation and the presence of particular sets of 228 
mutations (with respect to the root sequence). This should help with the development of rapid, 229 
algorithmic genome labelling tools. This task will become more complex, but still tractable, as 230 
SARS-CoV-2 genetic diversity accumulates, increasing the chance of both homoplasies and 231 
reverse mutations. Classification algorithms based on lists of ‘lineage-defining’ mutations may 232 
be practical if they are frequently cross-checked and validated against phylogenetic estimations, 233 
but will not be as powerful as phylogenetic classification methods that make use of complete 234 
genome sequence data to identify relationships. We encourage the research community to 235 
develop software and online tools that will enable the automated classification of newly-236 
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generated genomes (one such implementation is pangolin, https://github.com/hCoV-237 
2019/pangolin).  238 
 239 
Coronaviruses also frequently recombine, meaning that a single phylogenetic tree may not 240 
always adequately capture the evolutionary history of SARS-CoV-2. Although this can make 241 
phylogenetic analysis challenging, recombination is readily accommodated within this system of 242 
lineage naming and assignment. A distinct recombination event, if it establishes onward 243 
transmission, will create a new viral lineage with a distinct common ancestor. Because this new 244 
lineage doesn’t have a single ancestral lineage they will be assigned the next available 245 
alphabetical prefix.  246 
 247 
While we believe that our proposed lineage nomenclature will greatly assist those working with 248 
COVID-19, we do not see it as exclusive to other naming systems, particularly those that are 249 
specifically intended to track lineages circulating within individual countries for which a finer 250 
scale will be helpful. Indeed, there are likely to be strong sampling biases toward particular 251 
countries. Further, we note that future genome sequence generation may require adjustments to 252 
the current proposal, and any such changes will be detailed at http://cov-lineages.org/. We 253 
envisage, however, that the general approach described here may be readily adopted for these 254 
purposes, and also for other viral epidemics where real-time genomic epidemiology is being 255 
undertaken. We expect that this dynamic nomenclature will be most useful for the duration of the 256 
global pandemic, which may last a few years. After that time, SARS-CoV-2 will be either 257 
globally eliminated or, more likely, become an endemic or seasonal infection. The remaining 258 
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endemic/seasonal lineages, which will by then be genetically distinct, can simply retain in the 259 
post-pandemic period their names from the dynamic nomenclature system. 260 
 261 
Methods 262 
We downloaded all SARS-CoV-2 genomes (at least 29,000bp in length) from GISAID on May 263 
18th 2020. We trimmed the 5’ and 3’ untranslated regions and retained those genomes with at 264 
least 95% coverage of the reference genome (Wuhan-Hu-2019, GenBank accession MN908947). 265 
We aligned these sequences using MAFFT’s FFT-NS-2 algorithm and default parameter 266 
settings12. We then estimated a maximum likelihood tree using IQ-TREE 213 using the GTR+Γ 267 
model of nucleotide substitution14,15, default heuristic search options, and ultrafast bootstrapping 268 
with 1000 replicates16.  269 
 270 
The maximum likelihood tree and associated sequence metadata were manually curated and the 271 
phylogeny was annotated with the lineage designations. This annotated tree, along with a table 272 
providing the lineage designation for each genome in the data set, is available for download at 273 
http://cov-lineages.org/. We also provide a high-resolution PDF figure of the entire tree labelled 274 
with lineages. These will be updated on a regular basis. Representative sequences from each 275 
lineage were selected to maximise within-lineage diversity and to minimise N-content and used 276 
to construct the maximum likelihood tree shown in Figure 1. 277 
 278 
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Figure Legends 347 
 348 
Fig. 1. Maximum likelihood phylogeny of globally sampled sequences of SARS-CoV-2 349 
downloaded from the GISAID database (http://gisaid.org) on May 18th 2020. Five representative 350 
genomes are included from each of the defined lineages. The largest lineages that are defined by 351 
our proposed nomenclature system are highlighted with coloured areas and labelled on the right. 352 
The remaining lineages defined by the nomenclature system are denoted by triangles. The scale 353 
bar represents the number of nucleotide changes within the coding region of the genome. 354 
  355 
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Table 1. Proposed nomenclature of early major lineages of SARS-CoV-2. See https://cov-356 
lineages.org/ for full details of each lineage. 357 
 358 
Lineage Genomes Date range Comments 
A 223 Jan-05, Apr-27 Root of the pandemic lies in this 
lineage, many Chinese sequences 
with global exports 
A.1 1116 Feb-20, Mar-25 Primary outbreak in Washington 
State, USA 
A.2 295 Feb-26, Apr-27 European lineage 
A.3 191 Jan-28, Apr-21 USA lineage 
A.5 118 Feb-23, Apr-26 European lineage 
B 1713 Dec-24, May-03 Base of this lineage lies in China 
with a lot of global travel between 
multiple locations 
B.1 7438 Jan-24, May-10 Comprises the large Italian 
outbreak, now represents many 
European outbreaks, with travel 
within Europe and from Europe to 
the rest of the world 
B.1.1 6286 Feb-15, May-09 Major European lineage, exports 
 20
to the rest of the world from 
Europe 
B.2 917 Feb-13, May-04 With B.1, comprises the large 
Italian outbreak 
B.3 752 Feb-23, Apr-23 UK lineage 
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